Last checked at 7 Jun 2021 07:00
Nuformix plc
("Nuformix" or the "Company")
Notice of Allowance of Patent in US
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that it has received a Notice of Allowance for a U.S. National Phase Patent Application No. 17/051,592 entitled "CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE".
NXP002 is the Company's pre-clinical lead asset and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF"). It is a repurposed, new form of the drug tranilast, to be delivered in an inhaled formulation. Nuformix filed two patent applications on new crystalline forms of tranilast, one of which has been granted globally and this second patent application has now been allowed in the US and has also been approved for the "Patent Prosecution Highway" which may accelerate examination in other countries.
As previously communicated, since completing the successful fundraise in March 2021, Nuformix has started additional pre-clinical studies on NXP002 through outsourced expert contract organisations to generate a more robust data package with the goal of increasing the value of the NXP002 asset to render it more attractive to licensing partners.
Dr Anne Brindley, CEO of Nuformix, said: "I am very pleased that we have received this Notice of Allowance from the US Patent Office meaning that this patent will proceed to be issued. This is an important endorsement of Nuformix's discoveries and also strengthens the patent estate for our lead asset NXP002. The US is the largest market for IPF (over 60% of the global market) and thus this is a key step forward for the Company and this asset."
Enquiries:
Nuformix plc | +44 (0)1223 627 222 |
Dr Anne Brindley, CEO |
|
|
|
Allenby Capital Limited | +44 (0)20 3328 5656 |
Nick Athanas / George Payne (Corporate Finance) |
|
Tim Sohal / Matt Butlin (Sales & Corporate Broking) |
|
|
|
Walbrook PR | +44 (0)20 7933 8780 or nuformix@walbrookpr.com |
Anna Dunphy / Paul McManus / Kiki Zaccagnini |
|
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com